COVID antibody drug tested in kids – but study stopped early
NCT ID NCT05092581
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a single dose of casirivimab+imdevimab (REGN-COV2) in children hospitalized with COVID-19. The goal was to see how the drug behaves in the body and whether it is safe. However, the study was terminated early and only enrolled 2 participants, so we have very little information from it.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- casirivimab+imdevimab (REGN-COV2, a combination of two monoclonal antibodies)
- What this could lead to
- If successful, this could provide a treatment option for hospitalized children with COVID-19.
- What could go wrong
- This was a very early (Phase 1) study that was terminated after enrolling only 2 participants, so results are extremely limited and may not be reliable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Le Bonheur Children's Hospital
Memphis, Tennessee, 38103, United States
-
State University of New York at Stony Brook
Stony Brook, New York, 11794, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?